Roche license
Executive Summary
Three Roche products, Mestinon, Prostigmin and Tensilon, licensed by ICN for treatment of myasthenia gravis. ICN will pay Roche royalties on product sales. Roche receives first rights to "certain new molecular entities" developed at NARI.